Abstract
We conducted a population-based cohort study using administrative databases to quantify the association between oral and inhaled corticosteroid use and onset of diabetes mellitus in the elderly. Proton pump inhibitor (PPI) users were used as a control group. Relative to PPI users (N=53,845), oral corticosteroid users (N=31,864) were more likely to develop diabetes (adjusted rate ratio [aRR], 2.31; 95% confidence interval [95% CI], 2.11 to 2.54); however, inhaled corticosteroid users (N=38,441) were not (aRR, 1.03; 95% CI, 0.93 to 1.14). The estimated number needed to harm for continuous use of oral corticosteroids relative to PPIs over 1, 2, and 3 years of use were 41, 23, and 16, respectively.
References
Delaunay F, Khan A, Cintra A, et al. Pancreatic β cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest. 1997;100:2094–8.
Conn H, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–32.
Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol. 1972;49:329–36.
Smyllie H, Connolly C. Incidence of serious complications of corticosteroid therapy in respiratory disease. Thorax. 1968;23:571–81.
Jindal R, Sidner R, Milgrom M. Post-transplant diabetes mellitus: the role of immunosuppression. Drug Saf. 1997;16:242–57.
Gurwitz J, Bohn R, Glynn R, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97–101.
Faul JL, Tormey W, Tormey V, Burke C. High dose inhaled corticosteroids and dose dependent loss of diabetic control. BMJ. 1998;317:1491.
Faul JL, Cormican LJ, Tormey VJ, et al. Deteriorating diabetic control associated with high-dose inhaled budesonide. Eur Respir J. 1999;14:242–3.
Hux J, Bica A, Flintoft V, Ivis F. Population based estimates of the incidence and the prevalence of diabetes in Ontario. Diabetes. 2000;49(Suppl 1):388.
Blanchard JF, Ludwig S, Wajda A, et al. Incidence and prevalence of diabetes in Manitoba, 1986–1991. Diabetes Care. 1996;19:807–11.
Robson J. Information needed to decide about cardiovascular treatment in primary care. BMJ. 1997;314:277–80.
Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients’ acceptance of treatment. Med Decis Making. 1995;15:152–7.
McAlister FA, O’Connor AM, Wells G, Grover SA, Laupacis A. When should hypertension be treated? The different perspectives of Canadian family physicians and patients. CMAJ. 2000;163:403–8.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dr. Hux is a career scientist of the Ontario Ministry of Health and Drs. Hux and Mamdani receive salary support from the Institute for Clinical Evaluative Sciences in Ontario.
Rights and permissions
About this article
Cite this article
Blackburn, D., Hux, J. & Mamdani, M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J GEN INTERN MED 17, 717–720 (2002). https://doi.org/10.1046/j.1525-1497.2002.10649.x
Issue Date:
DOI: https://doi.org/10.1046/j.1525-1497.2002.10649.x